NASDAQ:NRSN

Neurosense Therapeutics Stock News

Healthcare > Biotechnology

Buy NRSN

*Your capital is at risk

$0.465

-0.0108 (-2.27%)

At Close: Jul 31, 2026

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

08:00am, Monday, 01'st Jul 2024

Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo Consistent data across multiple endpoints underscor

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

09:00am, Monday, 24'th Jun 2024

Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass. , June 24, 2024 /PR

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

04:30pm, Friday, 21'st Jun 2024

CAMBRIDGE, Mass. , June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

09:00am, Monday, 20'th May 2024

CAMBRIDGE, Mass. , May 20, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

09:05am, Tuesday, 14'th May 2024

PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- NeuroSense Therapeutics (

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

08:45am, Tuesday, 07'th May 2024

PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm CAM

NeuroSense Announces First Quarter 2024 Business Update

09:19am, Thursday, 02'nd May 2024

CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

08:30am, Monday, 22'nd Apr 2024

CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

08:30am, Thursday, 18'th Apr 2024

Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels CAMBRIDGE, Mass.

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

08:30am, Friday, 12'th Apr 2024

Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass. , April 12, 2024 /PRNewswire/ -- NeuroSense Therapeutics

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

07:16pm, Wednesday, 10'th Apr 2024

CAMBRIDGE, Mass. , April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

08:30am, Tuesday, 09'th Apr 2024

NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method util

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by